Literature DB >> 16828788

Development of an aqueous two-phase partitioning system for fractionating therapeutic proteins from tobacco extract.

Dimitris Platis1, Nikolaos E Labrou.   

Abstract

In the present study, an aqueous two-phase partitioning system (ATPS) was developed and evaluated as an initial fractionation step for therapeutic antibodies and enzymes from tobacco extracts. A detailed study has been performed to analyze the effect of pH, ionic composition of the system, types of polymers and their molecular weight and concentration, on the partitioning behavior of tobacco proteins and human anti-human immunodeficiency virus (HIV) monoclonal antibody 2F5 (mAb 2F5). A polyethyleneglycol/phosphate (PEG/Pi) aqueous two-phase system composed of 12% (w/w) PEG 1500 and 13% (w/w) phosphate buffer, pH 5, was selected as the system with the highest selectivity of antibody over native tobacco proteins. Under selected conditions, sufficient purification (3-4-fold) with high recovery at the bottom phase (approximately 95%) was achieved for mAb 2F5. In addition, the system allows removal of plant-derived compounds, such as phenolics and toxic alkaloids. The antibody fraction may be directly applied to a Protein A affinity column without any further pre-treatment, thus allowing homogenous antibody preparation. Analysis of the purified antibody fraction by enzyme-linked immunosorbent assay (ELISA) and western blot showed that the antibody was fully active and free of degraded variants or modified forms. The efficacy of the system was further demonstrated using additional proteins and enzymes of therapeutic importance, such as neuraminidase (NA) from influenza virus and human anti-HIV monoclonal antibody 2G12 (mAb 2G12), and showed that the system may find wide applicability as an economic extraction strategy for the initial fractionation of biopharmaceuticals from transgenic tobacco plants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828788     DOI: 10.1016/j.chroma.2006.06.047

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  6 in total

1.  Purification of the therapeutic antibody trastuzumab from genetically modified plants using safflower Protein A-oleosin oilbody technology.

Authors:  Michael D McLean; Rongji Chen; Deqiang Yu; Kor-Zheng Mah; John Teat; Haifeng Wang; Steve Zaplachinski; Joseph Boothe; J Christopher Hall
Journal:  Transgenic Res       Date:  2012-03-02       Impact factor: 2.788

Review 2.  Recent advances towards development and commercialization of plant cell culture processes for the synthesis of biomolecules.

Authors:  Sarah A Wilson; Susan C Roberts
Journal:  Plant Biotechnol J       Date:  2011-11-08       Impact factor: 9.803

3.  Optimisation of the purification process of a tumour-targeting antibody produced in N. benthamiana using vacuum-agroinfiltration.

Authors:  Raffaele Lombardi; Maria Elena Villani; Mariasole Di Carli; Patrizia Brunetti; Eugenio Benvenuto; Marcello Donini
Journal:  Transgenic Res       Date:  2010-03-15       Impact factor: 2.788

4.  Downstream processing of biopharmaceutical proteins produced in plants: the pros and cons of flocculants.

Authors:  Johannes Felix Buyel; Rainer Fischer
Journal:  Bioengineered       Date:  2014-02-03       Impact factor: 3.269

Review 5.  Viral vectors for production of recombinant proteins in plants.

Authors:  Chiara Lico; Qiang Chen; Luca Santi
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

Review 6.  Integrating plant molecular farming and materials research for next-generation vaccines.

Authors:  Young Hun Chung; Derek Church; Edward C Koellhoffer; Elizabeth Osota; Sourabh Shukla; Edward P Rybicki; Jonathan K Pokorski; Nicole F Steinmetz
Journal:  Nat Rev Mater       Date:  2021-12-06       Impact factor: 76.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.